Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

NMN-primed exosomes derived from infrapatellar fat pad mesenchymal stem cells exert synergistic anti-inflammatory and cartilage-protective effects via MERTK pathway activation in knee osteoarthritis.

Chen KT., Huang CC., Yadav VK., Pikatan NW., Fong IH., Kuo KT.

Animal Study on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Chronic Inflammation, published in Int J Pharm (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Pharm (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41213482
DOI
10.1016/j.ijpharm.2025.126367

Abstract (original English)

Osteoarthritis (OA) is a chronic degenerative joint disease lacking effective disease-modifying therapies. This study evaluated the therapeutic potential of nicotinamide mononucleotide (NMN)-primed exosomes derived from infrapatellar fat pad mesenchymal stem cells (IPFP-MSCs), termed Exo NMN(+) , under the hypothesis that NMN priming enhances their anti-inflammatory, antioxidant, and chondroprotective efficacy through MERTK-dependent signaling. Exo NMN(+) were isolated and characterized by nanoparticle tracking analysis and Western blotting, showing enrichment of exosomal markers (CD9, CD63, ALIX) without size alteration, indicating enhanced cargo loading. In IL-1β-stimulated human chondrocytes, Exo NMN(+) improved viability, migration, and proliferation (increased Ki-67 and EdU expression), suppressed catabolic factors (MMP2, MMP9, VEGF), and upregulated anabolic markers (COL2A1, MERTK). Transcriptomic profiling identified 428 uniquely regulated genes, primarily involved in PI3K-AKT and small-GTPase signaling. Intersection analysis with single-cell OA datasets revealed five shared differentially expressed genes forming the basis of the GAS6-MERTK-PI3K/AKT axis. Exo NMN(+) also reduced intracellular reactive oxygen species (by 51 %) and apoptosis (by 60 %), effects abrogated upon MERTK knockdown, confirming pathway specificity. In a papain-induced OA mouse model, intra-articula

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsExosomesAnimalsHumansOsteoarthritis, KneeAdipose TissueSignal Transductionc-Mer Tyrosine KinaseChondrocytesMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research